By G HossainPosted on June 8, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs The acquisition gives Johnson & Johnson access to Firefly Bio’s next-gen platform designed to create degrader antibody conjugates that can crack the tricky KRAS cancer target. J&J glows with $1B buyout of Firefly and its degrader platform tech Post navigation Fulcrum axes 85% of staff after walking away from lead assetADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold